# Paratek Pharmaceuticals

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/paratek-pharmaceuticals

- Industry: Pharmaceuticals
- Headquarters: King of Prussia, US
- Website: www.paratekpharma.com
- Total disclosed funding: $30M
- Latest round: Series D (Apr 26, 2002)
- Investors on record: 10

## About

Paratek Pharmaceuticals, Inc. is a U.S.-based biopharmaceutical company focused on developing and commercializing innovative therapies to combat antimicrobial resistance, particularly through its flagship product, NUZYRA®, targeting severe bacterial infections.Paratek Pharmaceuticals, Inc. specializes in developing antibiotic solutions, particularly for resistant bacterial strains. The company was founded in 1996 and is headquartered in Boston, Massachusetts. Paratek was formed after a merger with Transcept Pharmaceuticals, Inc. in 2014, which has informed its strategic direction. The company has successfully raised USD 462 mn in its most recent funding round on April 27, 2015, from investors including Gurnet Point Capital and Novo Holdings, which has enabled its ongoing expansion and product development.Paratek Pharmaceuticals specializes in the development and commercialization of innovative therapies focused on addressing antimicrobial resistance (AMR). The company's core product, NUZYRA®, is an antibiotic that targets a range of bacterial infections, including those caused by resistant strains. This product is designed for patients suffering from conditions such as community-acquired bacterial pneumonia and acute bacterial skin and skin structure infections, providing an essential solution in the fight against superbugs. Paratek’s offerings are primarily utilized in the U.S. and select international markets, serving hospitals, healthcare providers, and specialty pharmacies that cater to patients requiring advanced antibiotic therapies. The company’s commitment to research and development aims to expand its product portfolio, addressing urgent medical needs across the globe.Paratek Pharmaceuticals generates revenue through the sale of its flagship product, NUZYRA®, to healthcare providers and institutions, with revenue reported at USD 160.27 mn for the year 2022. The company’s structure relies on direct sales to hospitals and clinics, where products are crucial for treating serious bacterial infections. Paratek's transactions include agreements with hospitals and healthcare networks ensuring timely access for patients, aligned with the critical nature of its therapeutic applications.. The company is targeting expansion into new markets and geographic regions, focusing on international healthcare systems that require advanced antibiotic solutions. In March 2026, Radius Health, Inc., a portfolio company of Gurnet Point Capital and Patient Square Capital, merged with Paratek Pharmaceuticals, Inc., a portfolio company of Gurnet Point Capital. As part of the transaction, Sixth Street and Blackstone provided USD 1.3 billion in debt financing to support the merger.

## Funding rounds

- Series D, Apr 26, 2002, $30M — BioVeda Capital, HBM Partners, Novartis Venture Fund, Wheatley Partners, GeneChem, Pod Investment, Lombard Odier Asset Management, CDIB Capital Group, Nomura Asset Management, BankInvest

## Investors

- BioVeda Capital (https://capitalatlas.ai/funds/bioveda-capital) — Series D
- HBM Partners (https://capitalatlas.ai/funds/hbm-partners) — Series D
- Novartis Venture Fund (https://capitalatlas.ai/funds/novartis-venture-fund) — Series D
- Wheatley Partners (https://capitalatlas.ai/funds/wheatley-partners) — Series D
- GeneChem (https://capitalatlas.ai/funds/genechem) — Series D
- Pod Investment (https://capitalatlas.ai/funds/pod-investment) — Series D
- Lombard Odier Asset Management — Series D
- CDIB Capital Group (https://capitalatlas.ai/funds/cdib-capital-group) — Series D
- Nomura Asset Management (https://capitalatlas.ai/funds/nomura-asset-management) — Series D
- BankInvest (https://capitalatlas.ai/funds/bankinvest) — Series D